IDでもっと便利に新規取得

ログイン


ここから本文です

The midcap drugmaker Emergent BioSolutions said Wednesday it would collaborate with the Mount Sinai Health System to test a drug derived from blood plasma taken from recovered Covid-19 patients. The company will test the drug as a prophylactic to prevent infection in health-care workers who have been exposed to the virus.